


SR-717

Cat. No.:	HY-131454
CAS No.:	2375421-09-1
Molecular Formula:	C ₁₅ H ₈ F ₂ LiN ₅ O ₃
Molecular Weight:	351.19
Target:	STING
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 20.83 mg/mL (59.31 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.8475 mL	14.2373 mL	28.4746 mL	
		5 mM	0.5695 mL	2.8475 mL	5.6949 mL	
		10 mM	0.2847 mL	1.4237 mL	2.8475 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (5.92 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.92 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SR-717 is a non-nucleotide STING agonist with EC ₅₀ s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity ^[1] .
In Vitro	SR-717 activates STING by inducing the same closed conformation, which thereby provides an avenue to explore this class of systemic STING agonist in diverse contexts, including antitumor immunity ^[1] . SR-717 (3.8 μM) induces the expression of PD-L1 in THP1 cells and in primary human peripheral blood mononuclear cells in a STING-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SR-717 (30 mg/kg intraperitoneal once-per-day for 1 week) shows antitumor activities in WT or Sting ^{gt/gt} mice ^[1] .

SR-717 (30 mg/kg intraperitoneally for 7 days) displays antitumor activity; promotes the activation of CD8⁺ T, natural killer, and dendritic cells in relevant tissues; and facilitates antigen cross-priming^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	WT or Sting ^{gt/gt} mice ^[1]
Dosage:	30 mg/kg
Administration:	Intraperitoneally; once-per-day for 1 week
Result:	Maximally inhibited tumor growth.

REFERENCES

[1]. Emily N Chin, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020 Aug 21;369(6506):993-999.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA